Cargando…

Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia

OBJECTIVE: To evaluate health care resource utilization in patients with schizophrenia who continued newly prescribed antipsychotic medications, compared with those switching to different treatments. METHODS: Adults with schizophrenia in the California Medicaid (MediCal) database who initiated treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noordsy, Douglas L, Phillips, Glenn A, Ball, Daniel E, Linde-Zwirble, Walter T
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915559/ https://www.ncbi.nlm.nih.gov/pubmed/20694186

Ejemplares similares

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia
por: Panish, Jessica, et al.
Publicado: (2013)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

Follow-up Care among Medicaid Patients with Schizophrenia treated with Antipsychotics in the Inpatient Setting
por: Farr, Amanda M., et al.
Publicado: (2014)

The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia
por: McCabe, Rosemarie, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Ren, Xinhua S, et al.
Publicado: (2009)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

The impact of antipsychotic adherence on acute care utilization
por: Perkins, Anthony J., et al.
Publicado: (2023)

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia
por: Lin, Dee, et al.
Publicado: (2023)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia
por: Lertxundi, Unax, et al.
Publicado: (2018)

Antipsychotic Medication Adherence and Healthcare Services Utilization in Two Cohorts of Patients with Serious Mental Illness
por: Forma, Felicia, et al.
Publicado: (2020)

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
por: Morken, Gunnar, et al.
Publicado: (2008)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
por: Tareke, Minale, et al.
Publicado: (2018)

Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia: Erratum
Publicado: (2018)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization
por: Markowitz, Michael, et al.
Publicado: (2013)

Why Do People With Schizophrenia Exercise? A Mixed Methods Analysis Among Community Dwelling Regular Exercisers
por: Ho, Patrick A., et al.
Publicado: (2018)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study
por: Cascino, Giammarco, et al.
Publicado: (2022)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
por: El Khoury, Antoine C., et al.
Publicado: (2020)

Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data
por: Stockbridge, Erica L., et al.
Publicado: (2021)

Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
por: Caqueo-Urízar, Alejandra, et al.
Publicado: (2020)

Antipsychotic switching tool
por: Keks, Nicholas, et al.
Publicado: (2019)

Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia
por: Duncan, Laramie E, et al.
Publicado: (2018)

Medicaid Behavioral Health Care Plan Satisfaction and Children's Service Utilization
por: Cook, Judith A., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_gfb3h1kcu2l1vppqi9rnqs61do